
	Where results make sense

Topic: Anakinra

Related Topics

Umbrella Corporation

Griffon

Osburh

Solar keratosis

Clanton

Airy

Clusty

Nayland

	Anakinra - Drug information from Medic8.com
		Anakinra blocks the biologic activity of naturally occurring IL-1, including inflammation and cartilage degradation associated with rheumatoid arthritis, by competitively inhibiting the binding of IL-1 to the Interleukin-1 type receptor, which is expressed in many tissues and organs.
		Due to the fact that anakinra decreases the immune response to antigens in general, vaccine efficacy may be reduced in patients receiving anakinra.
		Due to the specific mechanism of action of anakinra, a possible efficiency may be anticipated in patients with inflammatory joint diseases such as psoriatic arthritis, and spondylarthritis.
	www.medic8.com /medicines/Anakinra.html (0 words)

	anakinra medical facts from Drugs.com
		Anakinra reduces the actions of chemicals in the body that are involved in inflammatory and immune responses.
		Anakinra is used to treat the symptoms of moderate to severe rheumatoid arthritis in patients who have had an inadequate response to one or more antirheumatic drugs.
		Anakinra is in the FDA pregnancy category B. This means that it is not expected to harm an unborn baby.
	www.drugs.com /MTM/anakinra.html (0 words)

	Hotline - Anakinra (Kineret® ™) FDA Approved for Use in Rheumatoid Arthritis
		Anakinra is a biologic response modifier that acts by antagonizing the biologic effects of IL-1.
		Anakinra is a nonglycosylated, recombinant human IL-Ra and differs from endogenous human IL-1ra by the addition of an N-terminal methionine.
		The combined use of anakinra and a TNF inhibitor was tested in a small pilot study of 58 RA patients who had active synovitis despite etanercept therapy and were then given anakinra 100 mg qd along with etanercept 25 mg BIW.
	www.rheumatology.org /publications/hotline/1101anakinra.asp?aud=stu (0 words)

	MedlinePlus Drug Information: Anakinra
		Anakinra is used, alone or in combination with other medications, to reduce the pain and swelling associated with rheumatoid arthritis.
		Anakinra is in a class of medications called interleukin antagonists.
		Anakinra comes as a solution to inject subcutaneously (under the skin).
	www.nlm.nih.gov /medlineplus/druginfo/medmaster/a602001.html (1081 words)

	The Alternative of Anakinra
		Anakinra (Kineret) is a promising alternative for patients who don't respond well to conventional disease modifying antirheumatic drugs (DMARDs) like methotrexate (MTX).
		Anakinra is a man-made protein, an IL-1 receptor antagonist (IL-1Ra) that blocks excess IL-1 molecules looking for cartilage or tissue cells to call a home.
		When first discussing the possibility of anakinra, patients and their doctors need to take these risks into consideration; but for the patient who isn't responding to conventional treatment, anakinra may very well be worth the risk.
	www.creakyjoints.com /go/article0070.shtml (0 words)

	Anakinra - Drugs & Vitamins - Drug Library - DrugDigest
		ANAKINRA (Kineret®) is used for the treatment of rheumatoid arthritis in adults.
		Anakinra is often given in combination with other agents such as corticosteroids (examples: dexamethasone or prednisone), anti-inflammatory drugs, methotrexate, or other drugs to treat rheumatoid arthritis.
		Anakinra is given by a small injection under the skin once a day.
	www.drugdigest.org /DD/DVH/Uses/0,3915,550910\|Anakinra,00.html (0 words)

	CIGNA - Anakinra for rheumatoid arthritis
		Anakinra limits the action of an inflammatory substance known as interleukin (IL-1) that attaches to the joint surface and promotes inflammation.
		Anakinra is a disease-modifying antirheumatic drug (DMARD), which means it slows the progression of rheumatoid arthritis.
		Anakinra has been approved for use in adults with moderate to severe rheumatoid arthritis if at least one other DMARD is not effective.
	www.cigna.com /healthinfo/uh1145.html (0 words)

	Anakinra (Systemic) - MayoClinic.com
		Anakinra will not cure the disease, but will help with the symptoms as long as you continue to take it.
		Anakinra is not usually recommended for use in children.
		Your body's ability to fight infection may be reduced while you are being treated with anakinra, it is very important that you call your doctor at the first signs of any infection (for example, if you get a fever or chills).
	www.mayoclinic.com /health/drug-information/DR500349 (0 words)

	Safety of Kineret® (anakinra) in patients with RA
		Of the 2,606 patients treated with Kineret® (anakinra) across the RA studies, 1,812 were exposed for at least 6 months and 570 exposed for at least 1 year.
		Because concurrent administration of Kineret® (anakinra) and Enbrel® (etanercept) has been associated with an increased risk of serious infections, an increased risk of neutropenia, and has not demonstrated any additional therapeutic benefit compared with monotherapy, concurrent use of these agents is not recommended.
		The safety and efficacy of Kineret® (anakinra) used in combination with other TNF antagonists has not been established and their combined use is, therefore, also not recommended.
	www.kineret-eu.com /en/pro/abo/abosaf.jsp (1518 words)

	Anakinra (Kineret)
		Anakinra is a new interleukin-1 receptor antagonist (IL-1Ra) indicated for the reduction of signs and symptoms of moderately to severely active rheumatoid arthritis in patients 18 years of age or older who have failed one or more disease modifying antirheumatic drugs (DMARDs).
		Anakinra is 95% bioavailable and peak plasma concentrations occur 3 to 7 hours after subcutaneous administration in patients with rheumatoid arthritis.
		Anakinra is excreted renally unchanged, and the clearance is decreased 70% to 75% in patients with a creatinine clearance less than 30 ml/min.
	uuhsc.utah.edu /pharmacy/bulletins/anakinra.html (623 words)

	Anakinra for rheumatoid arthritis
		Anakinra limits the action of an inflammatory substance known as interleukin (IL-1) that attaches to the joint surface and promotes inflammation.
		Anakinra is a disease-modifying antirheumatic drug (DMARD), which means it slows the progression of rheumatoid arthritis.
		Anakinra has been approved for use in adults with moderate to severe rheumatoid arthritis if at least one other DMARD is not effective.
	www.webmd.com /rheumatoid-arthritis/Anakinra-for-rheumatoid-arthritis (518 words)

	Arthritis Research Campaign \| Drugs for Arthritis: Anakinra (Site not responding. Last check: )
		Anakinra (trade name Kineret) is a drug which blocks the action of a protein called interleukin-1 (IL-1).
		Anakinra reduces the activity of the immune system, and can lower the white blood count (that is, reduce the number of white blood cells).
		As yet, the long-term side-effects of anakinra are not known because it is a relatively new drug.
	www.arc.org.uk /about_arth/infosheets/6263/6263.htm (1129 words)

	anakinra - Arthritis and arthritic conditions, medications, and treatment on MedicineNet.com
		Anakinra attaches to the IL-1 receptor and prevents IL-1 from attaching to the receptor.
		Anakinra was approved by the Food and Drug Administration in November, 2001.
		STORAGE: Anakinra should be refrigerated at 2-8°C (36-46°F) Anakinra is used for treating the signs and symptoms of moderate to severe rheumatoid arthritis in individuals 18 years of age or older.
	www.medicinenet.com /anakinra/article.htm (0 words)

	Kineret (anakinra)
		Anakinra is a biologic used to treat inflammatory types of arthritis like rheumatoid arthritis.
		Anakinra is given by an injection under the skin every day.
		Any woman who is pregnant or may become pregnant should not take anakinra as it has not been studied in pregnant women.
	www.arthritis.ca /tips%20for%20living/understanding%20medications/biological%20response%20modifiers/kineret/default.asp?s=1 (247 words)

	Rheumatoid arthritis - anakinra
		Anakinra should not normally be used as a treatment for rheumatoid arthritis.
		Doctors should not stop prescribing anakinra for people who were already taking it at the time the guidance was issued.
		NICE says that these patients should continue taking anakinra until they and their consultants decide that it is the right time to stop treatment.
	www.nice.org.uk /page.aspx?o=94670 (0 words)

	USNews.com: Health: Rheumatoid Arthritis: Anakinra
		The most common side effects of anakinra in the clinical trials were redness, bruising, inflammation, and pain at the site of injection.
		In addition, anakinra should not be started in people with an active infection or continued if a serious infection develops (for example, one that requires treatment with an antibiotic).
		To monitor for this side effect, your doctor should test your blood before beginning treatment with anakinra; after treatment is begun, tests should be done monthly for the first three months and then every three months for up to a year.
	www.usnews.com /usnews/health/bones/rheumatoid_arthritis/ra.treat.newdrug.ana.htm (318 words)

	Combination Therapy with Etanercept and Anakinra for Rheumatoid Arthritis
		While the addition of anakinra to etanercept did not enhance efficacy, there was a trend towards a higher rate of serious infections in patients treated with the combination.
		However, the clear lack of added efficacy conveyed by the addition of anakinra to etanercept is reason enough to avoid this regimen in clinical practice.
		Anakinra's clinical efficacy in RA is relatively modest in comparison to etanercept, perhaps due to its relatively short half-life.
	www.hopkins-arthritis.som.jhmi.edu /news-archive/2004/etanercept_anakinra.html (798 words)

	EULAR: Anakinra (Interleukin-1 Receptor Antagonist) Arrests Joint Destruction, Improves Function In Rheumatoid Arthritis (Site not responding. Last check: )
		Anakinra also demonstrated health related quality of life benefits, as measured by the Nottingham Health Profile (NHP), in an additional analysis of the same patients, who were not receiving DMARD (disease-modifying anti-rheumatic drug) therapy.
		Anakinra arrests joint destruction in patients with RA and established erosions.
		Anakinra 0560 Study Group: Improvements in functional status due to anakinra therapy in patients with rheumatoid arthritis who are not using DMARDS.
	www.pslgroup.com /dg/1FE5BA.htm (1271 words)

	Datamonitor - Arthritis drug found to help debilitating inflammatory disease - News
		Anakinra is a biologic agent, a medicine based on compounds that are made by living cells and used to stimulate or restore the ability of the immune system to fight disease and/or infection.
		To determine the possible role of anakinra in treating NOMID, the researchers treated 18 NOMID patients (12 with identifiable CIAS1 mutations) aged four to 32 with daily doses of anakinra based on body weight.
		At month three, disease flared in 11 patients when they were withdrawn from anakinra as part of the study, but when anakinra was restarted, the disease quickly responded again.
	www.datamonitor.com /~5d1089ff7f1a4705a8322d4f18bb02e4~/companies/news/article/?pid=EE777479-82CB-4C21-AE5C-02113EC06438&type=NewsWire (638 words)

	Anakinra : Before Using - Kineret
		Anakinra has not been studied in pregnant women.
		However, anakinra has not been shown to cause birth defects or other problems in animal studies.
		Studies on this drug have been done only in adult diseaseds and there is no special info comparing use of anakinra in child with use in other age groups.
	drugs.medcatalog.net /anakinra/before-using.html (409 words)

	rheuma-online: Rheuma von A-Z: Anakinra
		Anakinra (Handelsname z.B. Kineret) ist ein neu entwickeltes Medikament zur Behandlung der chronischen Polyarthritis / rheumatoiden Arthritis.
		Anakinra ist der erste und bislang einzige Vertreter aus der Gruppe der biologischen Medikamente, die Interleukin-1 (IL-1) blockieren.
		Ebenso ist auch Anakinra wie jedes andere hochwirksame Medikament nicht vollkommen nebenwirkungsfrei.
	www.rheuma-online.de /a-z/a/anakinra.html (1042 words)

	Arch Dermatol -- Abstract: Phenotype, Genotype, and Sustained Response to Anakinra in 22 Patients With Autoinflammatory ...
		Arch Dermatol -- Abstract: Phenotype, Genotype, and Sustained Response to Anakinra in 22 Patients With Autoinflammatory Disease Associated With CIAS-1/NALP3 Mutations, December 2006, Leslie et al.
		Phenotype, Genotype, and Sustained Response to Anakinra in 22 Patients With Autoinflammatory Disease Associated With CIAS-1/NALP3 Mutations
		with interleukin 1 receptor antagonist (anakinra) in patients
	archderm.ama-assn.org /cgi/content/abstract/142/12/1591 (0 words)

	ANAKINRA - INJECTABLE
		USES: Anakinra is a protein medication used, either alone or in combination with other medications, to treat the symptoms of rheumatoid arthritis (e.g., pain, swelling).
		Anakinra is not a cure for rheumatoid arthritis.
		Anakinra is not recommended for other types of arthritis (e.g., osteoarthritis).
	www.personalmd.com /drgdb/345.htm (704 words)

	Full Text: Concomitant Medication Use in a Large, International, Multicenter, Placebo Controlled Trial of Anakinra, a ...
		Patients with RA with a wide range of comorbid conditions, disease activity, and background medications were randomly assigned in a 4:1 allocation ratio to treatment with anakinra 100 mg or placebo administered daily by injection.
		Safety was assessed by comparing adverse event profiles between anakinra and placebo patients according to concomitant medications received.
		This study indicates that anakinra has a good safety profile in patients typically seen in a rheumatology practice who are considered candidates for therapy with agents that are immunomodulatory and disease modifying.
	www.jrheum.com /abstracts/abstracts04/649.html (376 words)

	RemedyFind: patient ratings of Kineret (Anakinra) for Rheumatoid Arthritis (RA)
		Kineret (Anakinra) is a newly approved (U.S. FDA November 2001) biological response modifier medication (also known as BRM or biologic agent) for Rheumatoid Arthritis.
		Anakinra works by targeting immune system chemicals known as cytokines, which are proteins similar to hormones and which cause the inflammation and joint destruction seen in RA.
		The maximum benefit of anakinra on joint space narrowing was achieved within the first 24 weeks and was maintained during continued treatment, whereas the slowing of erosions by anakinra increased with continued treatment beyond 24 weeks.
	www.remedyfind.com /rm-3029-Kineret.asp (1326 words)

	INTERLEUKIN-1 IN RHEUMATOID ARTHRITIS: ITS INHIBITION BY IL-1Ra AND ANAKINRA
		Administration of anakinra to animals with experimental arthritis reduced inflammation and joint damage.
		In clinical trials, anakinra was reasonably well tolerated; however, injection site reactions were frequent and there was a slight increased risk of serious infection.
		Alone or in combination with methotrexate, anakinra significantly reduced the symptoms and clinical signs of RA at the American College of Rheumatology 20% response level.
	www.hwbooks.com /jpt/abstracts/volume23/march-april/86.html (313 words)

	In RA patients unresponsive to several DMARDs but who are PPD+ although the chest X-ray is negative, how long should ...
		Anakinra is a recombinant IL-1 receptor antagonist (IL-ra) which competitively binds to IL-1.
		Infection with TB has not been reported to date in patients receiving anakinra; thus, it appears to be safe to use in patients with a positive PPD.
		Prudence dictates treatment of latent TB in patients known to be PPD positive when anakinra is started, but treatment can begin concomitantly.
	www.hss.edu /professional-conditions_13689.asp (887 words)

	Using anakinra for adult rheumatoid arthritis Nurse Practitioner - Find Articles
		Anakinra (Kineret), an exogenous, recombinant, human IL- 1 receptor antagonist (rhIL- 1 ra), counterbalances the detrimental effects of the disease-- heightened activity of IL-1 in inflammation, bone erosion, and cartilage destruction.
		Anakinra blocks IL- 1-induced synovial inflammatory-cell infiltration, specifically reducing synovial tissue macrophage and T-cell infiltration.2 IL-- 1b mediates joint destruction, which stimulates cartilage and bone resorption and inhibits the synthesis of articular collagen and proteoglycan.12
		Anakinra's protective effects on the bone erosion of joint destruction occur at a slower rate than do the effects on cartilage degradation.
	www.findarticles.com /p/articles/mi_qa3958/is_200204/ai_n9076807 (626 words)

	Clinical Trial: Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease
		Anakinra, approved by The Food and Drug Administration for treating rheumatoid arthritis in adults, blocks a substance called IL-1 that may be an important factor in causing the inflammation in NOMID.
		At the end of the observation period, patients will be admitted to the NIH for a standardized clinical evaluation and initiation of treatment with anakinra administered at 1mg/kg/day by regular daily subcutaneous injections (study phase 1).
		The clinical improvement at 3-4 months and the change in serum amyloid A levels (a sensitive inflammatory marker) from before treatment to 3-4 months post treatment, change in SAA levels after 7 days of drug withdrawal and drug safety are the primary clinical outcomes of this study.
	clinicaltrials.gov /ct/show/NCT00069329 (1711 words)

Try your search on: Qwika (all wikis)